Last reviewed · How we verify
NCT02854163: SATURN
Effect of Secukinumab in the Treatment of Psoriatic Arthritis
Phase 2 trial testing Secukinumab in Psoriatic Arthritis in 30 participants. Completed in 18 September 2019.
18 September 2019
Quick facts
| Lead sponsor | University of Liverpool |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 15 October 2016 |
| Primary completion | 18 September 2019 |
| Estimated completion | 18 September 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Secukinumab (secukinumab) — full drug profile →
Conditions studied
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
Sponsor
University of Liverpool
Who can join
18 and older, any sex, with Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. As secondary, exploratory objectives, the investigators will utilise the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab, with respect to efficacy and adverse events. The results of this secondary exploratory analysis will inform the design of a larger, definitive study.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The role of neutrophil death in chronic inflammation and cancer.
Brostjan C, Oehler R. · · 2020 · cited 123× · PMID 32351713 · DOI 10.1038/s41420-020-0255-6 -
Interactions between neutrophils and T-helper 17 cells.
Fan X, Shu P, Wang Y, Ji N, et al · · 2023 · cited 51× · PMID 37920459 · DOI 10.3389/fimmu.2023.1279837 -
Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets.
Li L, Lu J, Liu J, Wu J, et al · · 2023 · cited 26× · PMID 38239345 · DOI 10.3389/fimmu.2023.1340677 -
Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions.
Jin P, Duan X, Huang Z, Dong Y, et al · · 2025 · cited 21× · PMID 40717128 · DOI 10.1038/s41392-025-02270-3
Verify or expand the search:
- PubMed search for NCT02854163
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Secukinumab
Trials testing the same drug.
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07477795 — Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients · Phase 2 · not yet recruiting
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
- NCT06751238 — Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in · Phase 1 · recruiting
Other recruiting trials for Psoriatic Arthritis
Currently open trials in the same condition.
- NCT07286058 — Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis · Phase 3 · recruiting
- NCT07295509 — A Study of Picankibart in Patients With Active Psoriatic Arthritis · Phase 2, PHASE3 · recruiting
- NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
- NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
- NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
Other University of Liverpool trials
Trials by the same sponsor.
- NCT07368881 — Fast Food Online Delivery Purchase Behaviour in the Presence and Absence of Price-based Incentives · NA · not yet recruiting
- NCT07339982 — Supermarket Labelling and Taxation Study · NA · not yet recruiting
- NCT07423845 — Nutri-score Labels on the Nutritional Quality of Out-of-home Food Selection · NA · recruiting
- NCT07339969 — Food Choice Among Individuals With an Eating Disorder Diagnosis · NA · recruiting
- NCT07103967 — Investigating the Effects of Calorie Information and Serving Size of Alcohol Products on Alcohol Consumption. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02854163 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Liverpool
- Last refreshed: 9 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02854163.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing